Appropriateness of Spironolactone Prescribing in Heart Failure Patients: A Population-Based Study

Journal of Cardiac Failure

Volumn 12, Issue 3, 2006, Pages 205-210

  Ko, Dennis T ^a,e   Juurlink, David N ^b,c,e   Mamdani, Muhammad M ^b,e   You, John J ^d,e   Wang, Julie T ^e   Donovan, Linda R ^e   Tu, Jack V ^b,c,e  

^a Division of Cardiology

^b SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY HEALTH NETWORK   (Canada)

^e INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

Author keywords

Appropriateness; heart failure; hyperkalemia; population based cohort; spironolactone

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAPTOPRIL; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; LISINOPRIL; LOOP DIURETIC AGENT; POTASSIUM; POTASSIUM SPARING DIURETIC AGENT; RAMIPRIL; SPIRONOLACTONE;

ADULT; AGED; ARTICLE; CANADA; CHRONIC KIDNEY FAILURE; COHORT ANALYSIS; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; GLOMERULUS FILTRATION RATE; HEART FAILURE; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; HYPERKALEMIA; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRESCRIPTION; PRIORITY JOURNAL; SUPPLEMENTATION;

AGED; ALDOSTERONE ANTAGONISTS; DRUG UTILIZATION REVIEW; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; HYPERKALEMIA; KIDNEY; MALE; PHYSICIAN'S PRACTICE PATTERNS; RISK ASSESSMENT; RISK FACTORS; SPIRONOLACTONE; SYSTOLE;

EID: 33646484997     PISSN: 10719164     EISSN: 15328414     Source Type: Journal    
DOI: 10.1016/j.cardfail.2006.01.003     Document Type: Article

References (27)

1. Pitt B., Zannad F., Remme W.J., Cody R., Castaigne A., Perez A., et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341 (1999) 709-717
2. Pitt B., Remme W., Zannad F., Neaton J., Martinez F., Roniker B., et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348 (2003) 1309-1321
3. Vasan R.S., Evans J.C., Larson M.G., Wilson P.W., Meigs J.B., Rifai N., et al. Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N Engl J Med 351 (2004) 33-41
4. Ghali W.A., and Cornuz J. Early uptake of research findings after fast-track publication. Lancet 355 (2000) 579-580
5. Juurlink D.N., Mamdani M.M., Lee D.S., Kopp A., Austin P.C., Laupacis A., et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 351 (2004) 543-551
6. Lee D.S., Austin P.C., Rouleau J.L., Liu P.P., Naimark D., and Tu J.V. Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. JAMA 290 (2003) 2581-2587
7. Levy D., Kenchaiah S., Larson M.G., Benjamin E.J., Kupka M.J., Ho K.K., et al. Long-term trends in the incidence of and survival with heart failure. N Engl J Med 347 (2002) 1397-1402
8. Association Heart Association. Heart Disease and Stroke Statistics-2004 Update (2003), American Heart Association, Dallas, Tex
9. Hunt S.A., Baker D.W., Chin M.H., Cinquegrani M.P., Feldman A.M., Francis G.S., et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 38 (2001) 2101-2113
10. Wrenger E., Muller R., Moesenthin M., Welte T., Frolich J.C., and Neumann K.H. Interaction of spironolactone with ACE inhibitors or angiotensin receptor blockers: analysis of 44 cases. BMJ 327 (2003) 147-149
11. Schepkens H., Vanholder R., Billiouw J.M., and Lameire N. Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases. Am J Med 110 (2001) 438-441
12. Berry C., and McMurray J. Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone. Am J Med 111 (2001) 587
13. Bozkurt B., Agoston I., and Knowlton A.A. Complications of inappropriate use of spironolactone in heart failure: when an old medicine spirals out of new guidelines. J Am Coll Cardiol 41 (2003) 211-214
14. Tu J.V., Donovan L.R., Lee D.S., Austin P.C., Ko D.T., Wang J.T., and Newman A.M. Quality of Cardiac Care in Ontario (2004), ICES, Toronto, Ontario
15. Tu J.V., Naylor C.D., and Austin P. Temporal changes in the outcomes of acute myocardial infarction in Ontario, 1992-1996. Can Med Assoc J 161 (1999) 1257-1261
16. Tu J.V., Pashos C.L., Naylor C.D., Chen E., Normand S.L., Newhouse J.P., et al. Use of cardiac procedures and outcomes in elderly patients with myocardial infarction in the United States and Canada. N Engl J Med 336 (1997) 1500-1505
17. McKee P.A., Castelli W.P., McNamara P.M., and Kannel W.B. The natural history of congestive heart failure: the Framingham study. N Engl J Med 285 (1971) 1441-1446
18. Vasan R.S., Larson M.G., Benjamin E.J., Evans J.C., Reiss C.K., and Levy D. Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: Prevalence and mortality in a population-based cohort. J Am Coll Cardiol 33 (1999) 1948-1955
19. Palmer B.F. Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. N Engl J Med 351 (2004) 585-592
20. Kidney Disease Outcome Quality Initiative. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 39 (2002) S1-S246
21. Pitt B. Aldosterone blockade in patients with systolic left ventricular dysfunction. Circulation 108 (2003) 1790-1794
22. Masoudi F.A., Havranek E.P., Wolfe P., Gross C.P., Rathore S.S., Steiner J.F., et al. Most hospitalized older persons do not meet the enrollment criteria for clinical trials in heart failure. Am Heart J 146 (2003) 250-257
23. Jha P., Deboer D., Sykora K., and Naylor C.D. Characteristics and mortality outcomes of thrombolysis trial participants and nonparticipants: a population-based comparison. J Am Coll Cardiol 27 (1996) 1335-1342
24. Lee P.Y., Alexander K.P., Hammill B.G., Pasquali S.K., and Peterson E.D. Representation of elderly persons and women in published randomized trials of acute coronary syndromes. JAMA 286 (2001) 708-713
25. Masoudi F.A., Wang Y., Inzucchi S.E., Setaro J.F., Havranek E.P., Foody J.M., and Krumholz H.M. Metformin and thiazolidinedione use in Medicare patients with heart failure. JAMA 290 (2003) 81-85
26. Shlipak M.G. Pharmacotherapy for heart failure in patients with renal insufficiency. Ann Intern Med 138 (2003) 917-924
27. 2001 Census of Canada. Statistics Canada. Available at: https://www12.statcan.ca/english/census01/home/index.cfm. Accessed October 5, 2004.